A subset of available tumors (with matched blood) from patients enrolled in a phase I clinical trial testing a recombinant poliovirus, published by Desjardins et al. NEJM 2018 (<a href="https://pubmed.ncbi.nlm.nih.gov/29943666/">PMID:29943666</a>), were analyzed by whole exome sequencing and RNA-seq. It was discovered that low tumor mutation burden correlated with survival outcome, and also discovered that low tumor mutation burden correlated with higher inflammatory gene signatures by RNA-seq.

Very Low Tumor Mutation Burden Identifies Inflamed Recurrent    Glioblastomas Responsive to Cancer Immunotherapy

Glioblastoma study with RNA-Seq, WXS data on dbGaP (34 participants)

Very Low Tumor Mutation Burden Identifies Inflamed Recurrent Glioblastomas Responsive to Cancer Immunotherapy

Description

Applying For Access

Summary